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Dr Kenneth Kesler (Indianapolis, Ind). Your finding that
disease-free interval and number of lesions removed does not
negatively influence survival challenges conventional wisdom
and further justifies an aggressive surgical approach, which is
becoming common practice at many institutions. Additionally,
your message that, at the end of the day, survival is probably
more a matter of adverse biology—such as the presence of
synchronous pulmonary or extrapulmonary metastases—than the
approach by which pulmonary metastases are removed, makes
sense. But I also agree with your conclusion that due to the diverse
nature of these cases analysis of larger cohorts are needed to
provide clearer distinctions.
Whereas your finding of no overall survival difference between
patients undergoing video-assisted thoracic surgery (VATS) or an
open approach is of interest, one might expect selection bias; for
example, with open surgery being performed more frequently in
higher risk subsets, such as patients with small, subcentimeter
lesions or patients with >5 lesions, both categories of which
represented approximately one-third of your series. Regardless
of any bias being present or not, providing more detailed
tumor characteristics between the 2 groups and considering
propensity-matched or risk-adjusted survival analysis using
these types of variables might be a better comparison of the
2 approaches. These types of analyses would also make a stronger
argument for the efficacy of VATS if no survival difference is
confirmed.
Twenty-seven patients were not included in your analysis.
Presumably most or all of those patients had incomplete initial
resection with poorer outcomes. Perhaps this is a matter for
another study, but did you analyze this subset with respect to tumor
characteristics and/or surgical approach? For example, it would be
important if a determination could be made regarding which
patients would not likely achieve an R0 resection and thereby
avoid futile surgery.
If a minimally invasive approach resulted in an incomplete
resection that might have been prevented with an open
approach, this could be another important issue. Do you have
any information on this group that might be helpful to guide us
with future surgical management?
Dr Reza. In terms of incomplete resection, the interval to
recurrence after VATS or open surgery was not found to be
different. I think it may be reasonable to postulate that achieving
complete resection was at least similar in both the VATS and
open surgery groups.
We have not looked at the outcomes for patients who underwent
incomplete resections. We believe that the literature has fairly
definitively indicated that those outcomes are worse overall. In
our case, these were not failed attempts at complete resection,
but largely patients who needed either a diagnostic procedure or1200 The Journal of Thoracic and Cardiovascular Surpalliation of a specific complication of a single lesion or subset
of lesions. Our program does offer palliation to patients for
whom it is believed a meaningful difference in quality of life
can be achieved at a reasonable cost of morbidity related to
surgery, but the real goal of our aggressive approach to meta-
stasectomy is improving longer-term outcomes.
Dr Kesler. A number of publications have emphasized
the importance of bimanual palpation of the collapsed lung to
occasionally identify CT occult disease. You mention total lung
palpation during VATS metastasectomy. Would you please
comment further on this technique? Along those same lines, did
you use any localizing procedures preoperatively for smaller,
deeper lesions in patients undergoing a VATS approach?
Dr Reza. The VATS approach that has been used more recently
at our institution allows for more complete palpation of the lung,
largely owing to the port placement of VATS incisions, so that
nearly the entire collapsed lung can be brought closer to the
surgeon’s finger, allowing further palpation or even bidigital
palpation between 2 fingers if not bimanual palpation. We looked
at the ability to detect lesions<5 mm intraoperatively, as well as
being able to detect radiographically occult disease. We found
that the rates were comparable between the VATS and open groups
in identifying lesions<5mm and also radiographically determined
occult disease intraoperatively. In those patients, we have been
able to observe that there may be no limit to the size or number
of lesions that can be successfully approached through VATS,
even compared with open thoracotomy. We are preparing these
observations for presentation elsewhere, but the decision
regarding VATS may be more related to the anatomic location of
certain lesions rather than their number or size. Additionally, we
did not utilize any localizing procedures preoperatively to identify
the metastases. We have found that even very deep lesions can
often be palpated through the collapsed lung, and with proper
placement of incisions the lung can be brought close enough to
the surgeon’s finger to enable such palpation via VATS.
Dr Kesler. Did any patient undergoing open metastasectomy in
your series have an unexpected finding at the time of surgery that
might not have been identified during a VATS approach, such as an
occult lung, peribronchial lymph node, or small pleural
metastasis?
Dr Reza. There were certainly many patients who had CT
occult lymph nodes or nodules in both the open and VATS groups
that were discovered at surgery and resected. Our VATS technique
does enable discovery of these CT occult lesions. Resections of
benign nodules were not counted as positive resections and are
therefore not reflected in the data I presented today.
Dr Kesler. Apparently the use of chemotherapy was not a
predictive variable in your series. Would you please share your
current strategy with respect to the use of chemotherapy in these
patients? As a corollary, if you are using chemotherapy mainly
in the neoadjuvant setting, have you investigated the response of
chemotherapy as it relates to survival?
Dr Reza. We did not observe any relationship between the use
of chemotherapy and survival, whether the chemotherapy was
related to the metastasis or treatment of the primary tumor.
Chemotherapy is sometimes recommended to our patients
before metastasectomy, largely based on an individual patient’s
larger clinical context. Rapidly recurrent metastasis after initialgery c April 2014
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Sresection, for example, or a perception of extensive disease that
may not be amenable to complete resection, or the involvement
of numerous small nodules that suggest a tip of the iceberg
situation may all be scenarios in which a patient might be more
likely to receive systemic therapy. The type of sarcoma, its rate
of growth, and its likelihood to respond to available regimens
also plays a role in this decision. We have not yet systematically
analyzed the results of chemotherapy use in our patients with
sarcoma; we have never randomized patients to chemotherapy,
so that analysis will be statistically very challenging. In terms of
final recommendations on a specific strategy, I cannot comment
on what those are.
Dr Daniel L. Miller (Atlanta, Ga). I enjoyed your presentation.
I think more and more of us are doing more VATS procedures for
metastatic disease.
I have just 1 comment and 1 question. About 7 to 5 days before
surgery, we will go over with a radiologist the areas that we are
going after, and he or she will list out what slice that nodule is
on and so forth. It is a great planning exercise. So when we get
in the operating room, we know that there are 3 in the upper
lobe, 2 in the middle, and so forth. I think that has really helped
us, because sometimes you come back at 4 months with another
CT scan and there will be 1 little guy that you didn’t get.
Were the lobectomies is your experiences related to central
disease or for multiple nodules? A lot of times, if a patient has
4 or 5 nodules—usually in the lower lobe because of perfusion
and so forth—then I will do a lobectomy, which is very easy
thoracoscopically, especially if they don’t have a lot of disease
on the other side. Please comment on the reason for the lobectomy.The Journal of Thoracic and CarDrReza.Many of the lobectomies were required because of the
position of the tumor, because wedging it out without taking the
lobe would have been difficult. The lobe was taken in those cases.
There are likely a few cases where patients had diffuse metastatic
disease in whom it made more sense to take the lobe, although I do
not know the exact number of cases for which this was the
situation.
Dr Miller. Also, for our really deep lesions, we will do a
fiducial, which will be placed by a member of the radiology
team, and then wewill do fluoroscopic guidance. That really helps.
You minimize the amount of lung that you take.
DrMarcelo Cypel (Toronto, Ontario, Canada). I think 1 of the
main end points we should be looking at in comparisons between
VATS and thoracotomy is the incidence of ipsilateral recurrence.
Have you looked at that specifically in these 2 groups?
Dr Reza. We did not specifically analyze for ipsilateral
recurrence, although the overall recurrence rates were very similar
between VATS and open surgery.
Dr Cypel. I think that will tell if you left some lesions behind in
your VATS approach or not.
Dr Walter J. Scott (Philadelphia, Pa). Would you please
describe for us your criteria for considering someone
unresectable?
Dr Reza. The designation of unresectable was determined by
the treating surgeon, generally based on the extent of the patient’s
pulmonary disease but also considering other factors, such
as extensive extrapulmonary disease. In our series, 32 out of
36 patients with resectable disease underwent resection. However,
there were no predetermined or established criteria used.diovascular Surgery c Volume 147, Number 4 1201
